If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.

After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.

Adults at high risk of melanoma recurrence and spread were able to stay cancer-free with personalized vaccines made with mRNA ...

Moderna and Merck have reported promising results from a trial of more than 1,000 melanoma patients showing that their ...

An experimental new vaccine that could help prevent the deadly skin cancer melanoma from coming back after treatment is ...

Merck and Moderna say their personalized cancer vaccine reduced melanoma recurrence and spread in a Phase 3 trial.

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before ...

People given the experimental vaccine with standard treatment lived longer without their cancer returning, the companies ...

Moderna’s cancer vaccine results doubled its stock price after taxpayers paid to help develop it.

Check out some of the companies making the biggest moves midday: Walmart — The largest brick-and-mortar retailer in the nation tumbled 9%. Walmart second-quarter revenue topped estimates, but ...

Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its ...

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...